Rebecca earned her B.A. at UC Berkeley in 2000. Prior to her work at Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MPBC) she worked in clinical research and development at Chiron/Novartis starting in 2001, working on sepsis and monitoring and managing vaccine trials. In 2009, she joined MAPS as a part-time contractor and has since been working with them on MDMA/PTSD studies. In 2015, Rebecca joined MPBC full-time as a Clinical Trial Leader to work on the Marijuana/PTSD study as well as continuing to support MDMA studies.